Many medications are permitted alone or in combination with chemotherapy for colorectal cancer, non-small-cell lung cancer, and breast cancer due to the success of EGFR-targeting in the treatment of cancer (Wykosky et al., 2011; Chan et al., 2017; Thomas and Weihua 2019). Here, EGFR is linked to non-small cell lung carcinoma.